February 26, 2016
Half-Yearly Cash Flow and Activities Report – GSS Appendix 4D 31 December 2015
January 29, 2016
Quarterly Cash Flow & Activities Report – GSS Amended Appendix 4C 31 December 2015
November 6, 2015
University of California Los Angeles to Collaborate with Genetic Signatures on Transformative Molecular Platform Technology
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced a collaboration with Dr. Scott Binder MD and his Microbiology team at the University of California, Los Angeles (UCLA) to analyze molecular testing methods for bacteria, viruses and parasites as compared to traditional testing in an effort to reduce the spread of infection in the US healthcare system.
October 30, 2015
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 September 2015
October 20, 2015
GSS CEO Presentation at the 6th Annual Australian Microcap Investment Conference
- The largest conference in Australia focussed on emerging companies
- Presentations will be given by the CEOs of 20 of Australia’s leading microcaps
- Genetic Signatures to present its global growth strategy for the development and supply of world leading diagnostic solutions
Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that Chief Executive Officer, John Melki, PhD., will deliver today at the 6th Annual Australian Microcap Investment Conference.
Dr Melki will present on Genetic Signatures’ technology, commercialisation progress, financial results, and track record. The presentation will also detail the Company’s global revenue growth strategy for the sale of world leading solutions for the rapidly growing infectious disease detection market.
Dr Melki said: “It is pleasing that Genetic Signatures is seen as one of Australia’s leading microcap investment opportunities. It is an exciting time for the Company and I am looking forward to sharing the news of our success to date and plans for future global expansion and growth.”
October 1, 2015
Resignation of Director
Genetic Signatures Limited announces the resignation of Mr Patrick Noland as a Non- executive Director of the company to take up his new position in the company as Executive Vice President, US Operations. On September 22, 2015 Genetic Signatures announced the appointment of Mr Patrick Noland to the full-time position of Executive Vice President of US Operations.
September 29, 2015
Change of registered office address
Genetic Signatures Limited (ASX: GSS) advises effective today the Company’s registered office details have changed to:
Level 12,
680 George Street, Sydney NSW 2000.
Ph: +61 2 8280 7100
September 28, 2015
Date of 2015 Annual General Meeting
Genetic Signatures Limited (ASX: GSS) advises that its 2015 Annual General Meeting will be held on Monday 9 November 2015.
September 24, 2015
GSS Non-Deal Roadshow – 2015 Full Final Year Results Presentation
This presentation provides an update on the 2015 Full Final Year Results.
GSS Non-Deal Roadshow – 2015 Full Final Year Results Presentation
September 22, 2015
Genetic Signatures launches North America Commercial Operations
- Key appointment to drive North America Market Entry
- Complements Global Strategy for Product Commercialisation
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced the appointment of Patrick Noland to Executive VP, US Operations.
“We are thrilled to bring Pat on board as we launch US commercial operations for our molecular diagnostics platform,” said Genetic Signatures’ Chief Executive Officer, John Melki, PhD. “Pat’s decades of experience in the commercialisation of advanced biological testing services are a perfect fit for our US strategy as we introduce our recently listed FDA solution to the market.”
Prior to joining Genetic Signatures, Mr. Noland was the CEO of StrataDX, an anatomic pathology laboratory based in Lexington, Massachusetts. Prior to his tenure at StrataDX, Mr. Noland spent 17 years in sales leadership roles at Laboratory Corporation of America® Holdings (LabCorp®, NYSE:LH), a clinical-laboratory company with over $5 billion in annual revenue. In his last role at LabCorp, Pat served as Senior Vice President responsible for developing and implementing a new partnerships-focused hospital strategy, designed to expand the available US market. He holds a MBA from Kennesaw State University in Georgia and a BSc from the University of Georgia in Athens.